Entera Bio Ltd.

NASDAQ:ENTX

Biotechnology

Healthcare
$3.26 +0.00%

+$0.00 today

Market cap
$567.69M
Beta
1.49
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.91High $3.22

Volume 0.49M

Average 0.16M

ENTX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Entera Bio Ltd.NASDAQ: ENTX

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin not reported for Q1 FY2026

Over 3 fiscal years it narrowed by 17481.2 pp.

Context

  • Net margin widened in 1 of the last 2 fiscal years.
  • FY2025 was the lowest level in the 3 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 3 analysts of -42.1% for the fiscal year ending Dec 2026, up from -27235.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-27235.7%-21964.4 pp YoY
LTMMar 2026
—— YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-21964.4 pp+27193.6 pp+49158.1 pp
3 years-17481.2 pp-859766.7 pp-842285.4 pp
5 years+27199.5 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-27235.7%
Year-over-year change
-21964.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ENTX compares with its peers on the latest reported figures

  • ENTX's FY2025 net margin of -27235.7% is the 6th highest of the 7 companies compared; the peer median is -680.6%.
  • Its year-over-year change of -21964.4 pp is the 5th highest of 6, against a peer median of +97.4 pp.
  • Over three fiscal years its change of -17481.2 pp compares with a peer median of +109.9 pp.
ENTX Competitors Peer median
Net Margin for ENTX and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 202652.2% +243.7 pp+224.6 pp
SPROSpero Therapeutics, Inc.LTM Mar 202627.8% +184.3 pp+109.9 pp
SEERSeer, Inc.LTM Mar 2026-468.7% +97.4 pp+176.5 pp
IRDOpus Genetics, Inc.LTM Mar 2026-892.4% -462.9 pp-394.2 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-4088.8% ——
ENTXEntera Bio Ltd.FY2025-27235.7% -21964.4 pp-17481.2 pp
INOInovio Pharmaceuticals, Inc.FY2025-130000.0% -80745.7 pp-127273.3 pp
ANIXAnixa Biosciences, Inc.FY2025— ——
HURATuHURA Biosciences, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ENTX) -680.6%+97.4 pp+109.9 pp

Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue571K134K0181K42K
Cost of Revenue373K165K56K172K42K
Gross Profit198K(31K)(56K)9K0
Gross Margin34.7%-23.1%—5.0%0.0%
Research & Development6.77M5.78M4.45M4.5M6M
Selling, General & Admin5.69M7.25M4.43M5.1M5.53M
Operating Expenses12.42M13.04M8.88M9.59M11.53M
Depreciation & Amortization53K64K56K46K30K
EBITDA(12.16M)(12.87M)(8.8M)(9.48M)(11.41M)
EBITDA Margin-2130.3%-9604.5%—-5238.1%-27164.3%
Operating Income(12.22M)(13.07M)(8.94M)(9.59M)(11.53M)
Operating Margin-2139.6%-9752.2%—-5295.6%-27450.0%
Interest Income083K31K58K0
Interest Expense29K0000
Other Income / Expenses(29K)134K80K58K90K
Income Before Tax(12.25M)(12.93M)(8.86M)(9.53M)(11.44M)
Pre-Tax Margin-2144.7%-9652.2%—-5263.5%-27235.7%
Income Tax Expense(59K)137K29K14K0
Net Income(12.19M)(13.07M)(8.89M)(9.54M)(11.44M)
Net Margin-2134.3%-9754.5%—-5271.3%-27235.7%
EPS (Basic)(0.47)(0.45)(0.31)(0.25)(0.25)
EPS (Diluted)(0.47)(0.45)(0.31)(0.25)(0.25)
Weighted Avg Shares26.13M28.81M29.01M37.65M46.19M
Weighted Avg Shares (Diluted)26.13M28.81M29.01M37.65M46.19M

Entera Bio Ltd.

NASDAQ:ENTX

Intrinsic Alpha fair value

Locked

Current Price

$3.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.